UBS Group’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-2,056
| Closed | -$4.93K | – | 10497 |
|
|
2024
Q2 | $4.93K | Buy |
+2,056
| New | +$7.28K | ﹤0.01% | 8038 |
|
|
2024
Q1 | – | Sell |
-78,125
| Closed | -$326K | – | 10274 |
|
|
2023
Q4 | $326K | Buy |
+78,125
| New | +$589K | ﹤0.01% | 5438 |
|
|
2023
Q3 | – | Sell |
-13
| Closed | -$365 | – | 10149 |
|
|
2023
Q2 | $365 | Buy |
+13
| New | +$402 | ﹤0.01% | 8274 |
|
|
2023
Q1 | – | Sell |
-55
| Closed | -$798 | – | 10777 |
|
|
2022
Q4 | $798 | Buy |
55
+15
| +38% | +$289 | ﹤0.01% | 10069 |
|
|
2022
Q3 | $1K | Buy |
+40
| New | +$1.03K | ﹤0.01% | 10111 |
|
|
2022
Q2 | – | Sell |
-159
| Closed | -$6K | – | 11184 |
|
|
2022
Q1 | $6K | Buy |
+159
| New | +$5.91K | ﹤0.01% | 9023 |
|
|
2021
Q4 | – | Sell |
-295
| Closed | -$21K | – | 10885 |
|
|
2021
Q3 | $21K | Buy |
295
+188
| +176% | +$21.4K | ﹤0.01% | 7125 |
|
|
2021
Q2 | $14K | Buy |
107
+92
| +613% | +$11.5K | ﹤0.01% | 7727 |
|
|
2021
Q1 | $2K | Sell |
15
-16
| -52% | -$2.03K | ﹤0.01% | 8663 |
|
|
2020
Q4 | $2K | Buy |
+31
| New | +$2.28K | ﹤0.01% | 8137 |
|
|
2020
Q3 | – | Sell |
-37
| Closed | -$3K | – | 8516 |
|
|
2020
Q2 | $3K | Sell |
37
-63
| -63% | -$4.28K | ﹤0.01% | 7571 |
|
|
2020
Q1 | $4K | Buy |
100
+96
| +2,400% | +$7.29K | ﹤0.01% | 7424 |
|
|
2019
Q4 | $0 | Sell |
4
-98
| -96% | -$7K | ﹤0.01% | 8489 |
|
|
2019
Q3 | $7K | Buy |
102
+29
| +40% | +$2.96K | ﹤0.01% | 7359 |
|
|
2019
Q2 | $9K | Sell |
73
-11
| -13% | -$1.63K | ﹤0.01% | 7149 |
|
|
2019
Q1 | $14K | Sell |
84
-10
| -11% | -$1.49K | ﹤0.01% | 6606 |
|
|
2018
Q4 | $14K | Buy |
+94
| New | +$21K | ﹤0.01% | 7056 |
|
Other funds holding ASLN
UBS Group's ASLN Position: Q3 2024 in Review
UBS Group sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q3 2024, closing a stake of 2,056 shares — an estimated $4.93K sold.
UBS Group first reported a position in ASLN in Q4 2018 and held it in 17 quarters. The position peaked at $326K in Q4 2023. 1 fund tracked by Wall St. Rank holds ASLN as of Q3 2024.
- UBS Group reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q3 2024 after selling out during the quarter.
- UBS Group sold 2,056 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q3 2024, an estimated $4.93K.
- UBS Group first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q4 2018 and held it in 17 quarters.
- UBS Group's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $326K in Q4 2023.
- 1 fund tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q3 2024.
Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.